Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Newsfile - Fri Nov 8, 6:04AM CST

Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Newsfile - Tue Oct 29, 5:56AM CDT

Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Newsfile - Wed Sep 25, 8:58AM CDT

Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Newsfile - Fri Aug 9, 6:06AM CDT

Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Newsfile - Tue Aug 6, 6:20AM CDT

Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies Newsfile - Tue Jul 30, 5:54AM CDT

Encinitas, California--(Newsfile Corp. - July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation Newsfile - Wed Jul 10, 6:14AM CDT

Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer,...

KPRX : 3.32 (-1.45%)
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors Newsfile - Mon Jul 1, 5:58AM CDT

Ken Gayron to Step Down as a Member of the Company's BoardEncinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced...

KPRX : 3.32 (-1.45%)
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board Newsfile - Tue Jun 25, 5:58AM CDT

Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences Newsfile - Mon May 20, 6:06AM CDT

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be...

KPRX : 3.32 (-1.45%)

Barchart Exclusives

3 Dividend Stocks to Buy Now With Yields of About 4% or More Barchart - Mon Nov 25, 6:30PM CST
Three dividend stocks, Kimco Realty, Perrigo Company, and Permian Resources, are highlighted as attractive options for investors seeking steady income, with yields of 3.9% or more and strong fundamentals across the real estate, healthcare, and energy sectors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot